Summary

for people ages 18 years and up (full criteria)
at Irvine, California and other locations
study started
estimated completion

Description

Summary

Evaluate the long-term safety of amifampridine phosphate in the symptomatic relief of antibody positive MuSK-MG.

Official Title

Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis

Keywords

Myasthenia Gravis, MuSK Muscle Weakness Myasthenia Gravis Amifampridine Amifampridine Phosphate

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participated in the MSK-002 study

You CAN'T join if...

  • Epilepsy and currently on medication
  • Clinically significant abnormalities in ECG, in the opinion of the Investigator

Locations

  • UC Irvine not yet accepting patients
    Irvine California 92868 United States
  • University of Kansas Medical Center accepting new patients
    Fairway Kansas 66205 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Catalyst Pharmaceuticals, Inc.
ID
NCT03579966
Phase
Phase 3
Study Type
Interventional
Last Updated